Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Nicholas Butowski, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Nicholas Butowski, MD
Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Tango Therapeutics, Inc.
- ID
- NCT05275478
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 192 study participants
- Last Updated